AnaptysBio, Inc.Long
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Ca
ANAB: AnaptysBio, Inc.
2021-04-22 16:12:09
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer
2021-04-22 16:12:09
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.